Larazotide
Also known as Larazotide acetate · AT-1001 · zonulin antagonist
Investigational oral peptide for gut-barrier integrity studied mainly in celiac disease.
Evidence visual
Larazotide evidence and risk matrix
intermediate researcher fit
Evidence
Tier B
Risk
low
Regulatory
investigational
WADA
none
FDA
none
Route
oral
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Larazotide is an oral zonulin-pathway modulator studied for celiac disease and intestinal barrier function. Human safety data are relatively clean for an investigational peptide, but efficacy remains indication-specific and it is not approved. It is most relevant as a gut-barrier research agent rather than a general-purpose wellness peptide.
Decision path
Where Larazotide fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Larazotide belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Zonulin-pathway antagonism intended to preserve tight-junction integrity and reduce pathologic intestinal permeability.
oral
Human trials typically used 0.25 mg to 8 mg orally three times daily before meals.
Potential reduction in gluten-triggered gut-barrier disruption and GI symptom burden in celiac-focused trial settings.
Barrier effects are expected quickly at the gut interface; symptom outcomes in studies are measured over days to weeks.
No clear formal contraindications identified, but evidence is limited outside celiac-disease research populations.
Clinical trials report good tolerability with adverse-event rates close to placebo.
Minimal systemic absorption means drug-drug interaction risk appears low.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Larazotide.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.